Chargement en cours...
The immune response‐related mutational signatures and driver genes in non‐small‐cell lung cancer
Immune checkpoint blockade (ICB) therapy has achieved remarkable clinical benefit in non‐small‐cell lung cancer (NSCLC), but our understanding of biomarkers that predict the response to ICB remain obscure. Here we integrated somatic mutational profile and clinicopathologic information from 113 NSCLC...
Enregistré dans:
| Publié dans: | Cancer Sci |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6676111/ https://ncbi.nlm.nih.gov/pubmed/31222843 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14113 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|